Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: A prospective analysis of a nested substudy of the NTCC randomised controlled trial

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 168-176

  Carozzi, Francesca ^a   Gillio Tos, Anna ^b   Confortini, Massimo ^a   Del Mistro, Annarosa ^c   Sani, Cristina ^a   De Marco, Laura ^b   Girlando, Salvatore ^d   Rosso, Stefano ^e   Naldoni, Carlo ^f   Palma, Paolo Dalla ^d   Zorzi, Manuel ^c   Giorgi Rossi, Paolo ^g   Segnan, Nereo ^e   Cuzick, Jack ^h   Ronco, Guglielmo ^e  

^a Istituto per lo Studio e la Prevenzione Oncologica   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^f Regione Emilia Romagna   (Italy)

^g Azienda Sanitaria Locale di Reggio Emilia   (Italy)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRAL CLEARANCE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 84873079859     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70529-6     Document Type: Article

References (34)

1. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
2. Ronco G, Meijer CJLM HPV screening: available data and recommendations for clinical practice. Curr Cancer Ther Rev 2010, 6:104-109.
3. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
5. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88.
6. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolau tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
7. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 2007, 16:196-204.
8. Khleif SN, DeGregori J, Yee CL, et al. Inibition of cyclin D-CDK4/CDK6 activity is associated with E2F-mediated induction of cyclin kinase inibitor activity. Proc Natl Acad Sci USA 1996, 93:4350-4354.
9. McLaughlin-Drubin ME, Crum CP, Münger K Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011, 108:2130-2135.
10. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008, 9:937-945.
11. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006, 98:765-774.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006, 7:547-555.
13. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone to conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008, 100:492-501.
14. Dalla Palma P, Giorgi Rossi P, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicentre randomized study. Am J Clin Pathol 2009, 132:125-132.
15. Richart RM Cervical intraepithelial neoplasia. Pathol Annu 1973, 8:301-323.
16. Gelman A, Rubin DB Inference from iterative simulation using multiple sequences. Satistical Science 1992, 7:457-511.
17. Spiegelhalter DJ, Thomas A, Best NG WinBUGS: technical Report 1999, MRC Biostatistics Unit, University of Cambridge, Cambridge.
18. European guidelines for quality assurance on cervical cancer screening 2008, Office for Official Publications of the European Communities, Luxembourg. 2nd edn. M. Arbyn, A. Anttila, J. Jordan (Eds.).
19. Ronco G, Segnan N HPV testing for primary cervical cancer screening. Lancet 2007, 370:1740-1742.
20. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011, 12:880-890.
21. Ozaki S, Zen Y, Inoue M Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011, 42:1007-1012.
22. del Pino M, Garcia S, Fusté V, et al. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009, 201:488.
23. Anschau F, Schmitt VM, Lambert AP, Gonçalves MA, Machado DC Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. Exp Mol Pathol 2009, 86:46-50.
24. Hariri J, Øster A The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007, 26:223-228.
25. Plummer M, Peto J, Franceschi S Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012, 130:2638-2644. for the International Collaboration of Epidemiological Studies of Cervical Cancer.
26. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102:315-324.
27. Wang JL, Zheng BY, Li XD, Angstorm T, Lindstrom MS, Wallin KL Predictive value of the alterations of p16INK4A, p14ARF, p53 and proliferationg cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004, 10:2407-2414.
28. Kirbis IS, Maxwell P, FleŽar MS, Miller K, Ibrahim M External quality control for immunocytochemistry on cytology samples: a review of UK NEQAS ICC (cytology module) results. Cytopathology 2011, 22:230-237.
29. Holladay EB, Logan S, Arnold J, Knesek B, Smith GD A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by Hybrid Capture 2 for the detection of cervical dysplasias/neoplasias. Cancer 2006, 108:451-461.
30. Wentzensen NM, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4A positive cells to identify women with cervical intraepithelial neoplasia. Cancer 2007, 111:58-66.
31. Schmidt D, Bergeron C, Denton KJ, Ridder R p16/Ki-67 dual stain cytology in the triage of ASCUS and LSIL Papanicolau cytology: results from the European equivocal or mildly abnormal Papanicolau cytology study. Cancer Cytopathol 2011, 119:158-166.
32. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposocpy referral population. Clin Cancer Res 2012, 18:4154-4162.
33. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011, 121:505-509.
34. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.